| Bioactivity | Erianin, often used as an antipyretic and analgesic agent, could inhibit IDO-induced tumor angiogenesis. |
| Invitro | Erianin is often used as antipyretic and analgesic agent. Erianin belongs to bibenzyl derivatives in structure, with the activity of anti-virus, anti-bacterial, as well as anti-benign prostatic hyperplasia. Erianin has obvious damage on 2LL-IDO cells, Erianin basically has no cytotoxicity on human normal liver cell line L02, and cell viability is maintained at around 85%[1]. Erianin inhibits the growth of HeLa cells and induces apoptosis in a dose‑ and time‑dependent manner, inducing cell cycle arrest at the G2/M stage. Erianin treatment also increases the expression of Bax and caspase‑3, but decreases levels of Bcl‑2 and phosphorylated‑ERK1/2[2]. |
| Name | Erianin |
| CAS | 95041-90-0 |
| Formula | C18H22O5 |
| Molar Mass | 318.36 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Su C, et al. Erianin inhibits indoleamine 2, 3-dioxygenase -induced tumor angiogenesis. Biomed Pharmacother. 2017 Apr;88:521-528. [2]. Li M, et al. Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal-regulated kinase signaling pathway. Oncol Lett. 2018 Oct;16(4):5006-5012. |